# Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

> **NCT02332720** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 413 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Uprifosbuvir
- **DRUG:** Elbasvir
- **DRUG:** Ruzasvir
- **DRUG:** MK-3682B
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT02332720
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-28
- **Primary completion:** 2016-09-19
- **Final completion:** 2017-05-03
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332720, "Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02332720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*